Click here to view the presentation slides and physician reference handout from this CME-certified series held at select American College of Cardiology state chapter meetings.
The 2012 guidelines for the diagnosis and management of stable ischemic heart disease (SIHD) present an extensive assessment of the evidence and key issues involved in the diagnosis, risk assessment, treatment, and follow-up of known or suspected SIHD. The guidelines also recommend involving patients in all diagnostic and treatment decisions regarding their care. Overall, the guidelines present a comprehensive summary of the management of SIHD and complement the Appropriateness Criteria for Revascularization, which state that percutaneous coronary intervention should only be considered for SIHD patients who have persistent symptoms, despite guideline-directed medical therapy (GDMT).
From initial diagnosis through chronic-disease management in SIHD, physicians should integrate the information from their clinical evaluations with patient preferences when making management decisions. Effective patient education and counseling should be based on a collaborative approach that acknowledges individual patient needs through an understanding of cognitive, behavioral, and social/cultural factors. Patients actively involved in care decisions are more likely to follow a treatment plan and engage in behaviors that can improve their health.
Christopher P. Cannon, MD
Executive Director of Cardiometabolic Trials
Harvard Clinical Research Institute
Professor of Medicine, Harvard Medical School
Senior Physician, Cardiovascular Division
Brigham and Women’s Hospital
Christopher P. Cannon, MD is a Professor of Medicine at Harvard Medical School and Senior Physician in the Cardiovascular Division at Brigham and Women’s Hospital. He earned his medical doctorate from Columbia University College of Physicians and Surgeons in New York, then completed his internal medicine residency at Columbia Presbyterian Medical Center and his cardiovascular fellowship at Brigham and Women’s Hospital.
Dr. Cannon has published more than 1000 original articles, reviews, or electronic publications in the field of acute coronary syndromes and prevention and has authored or edited 17 books. He has received numerous awards, including leadership awards from the American College of Cardiology and the American Heart Association.
As a Senior Investigator of the TIMI Study Group, he has been Principal Investigator of more than 15 multicenter clinical trials, including TACTICS-TIMI 18, PROVE IT, and the IMPROVE IT trial. Dr. Cannon also serves as Executive Director of Cardiometabolic Trials at the Harvard Clinical Research Institute (HCRI). He is leading the RE-DUAL PCI trial, studying novel anticoagulant strategies in patients with atrial fibrillation undergoing stenting, and collaborates on many other trials and registry projects in the fields of acute coronary syndromes, atrial fibrillation, diabetes, lipids, and prevention.
Peter P. Toth, MD, PhD, FAAFP, FICA, FAHA, FNLA, FCCP, FACC
Director of Preventive Cardiology, CGH Medical Center
Professor of Clinical Family and Community Medicine
University of Illinois School of Medicine
Professor of Clinical Medicine, Michigan State University
Adjunct Associate Professor of Medicine
Johns Hopkins University School of Medicine, Sterling, IL
Peter P. Toth, MD received his bachelor’s in biochemistry from Princeton University and a PhD in biochemistry from Michigan State University. He graduated from Wayne State University School of Medicine and completed residency training in family medicine at the University of Iowa Hospitals and Clinics. He is a member of Alpha Omega Alpha and Sigma Xi, and is a former President of the National Lipid Association. He is the current President of the American Board of Clinical Lipidology.
Dr. Toth has authored/co-authored more than 320 publications in medical and scientific journals and textbooks. He is Editor-in-Chief of the Year in Lipid Disorders and an Associate Editor for the Year Book of Endocrinology. He is co-editor of the textbooks Comprehensive Management of High Risk Cardiovascular Patients; Therapeutic Lipidology; Current Controversies in Dyslipidemia Management; Practical Lipid Management; Comprehensive Cardiovascular Care in the Primary Care Setting; Clinical Challenges in Hypertension vols I and II; Cardiac Lipoglucotoxicity; and Lipoproteins in Diabetes Mellitus. In addition, he has lectured on many topics in cardiovascular medicine throughout the world.
This program is intended for community cardiologists, interventional cardiologists, and other professionals who treat patients with SIHD.
At the conclusion of this activity, participants should be able to demonstrate the ability to:
- Incorporate evidence-based approaches to the diagnosis and risk assessment of SIHD patients, particularly those with atypical symptoms who might otherwise be improperly treated
- Adopt ACC/AHA SIHD guideline recommendations which state that all SIHD patients should initially be treated with guideline-directed medical therapy (GDMT)
- Develop methods for educating and engaging patients to empower and involve them in treatment decisions and monitoring of disease state
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit or the evaluation, please email email@example.com.
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
Method of Participation
To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will be emailed 2 weeks after submission of a completed evaluation form.
There is no fee associated with this program.
Event staff will be glad to assist you with any specials needs (e.g. physical, dietary, etc.). Please email firstname.lastname@example.org at least 5 days prior to the program.
Jointly PROVIDED By
|Jointly provided by
This activity has been supported by an educational grant from Gilead Sciences Medical Affairs
By clicking the Registration Button below you are agreeing that you have read and understood the CME/CE Statements above.
Registration is for planning purposes only. Seating is limited and will be provided on a first-come, first-served basis.